1. Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy

   • Cornelis Boersma
   • Jarir Atthobari
   • Maarten J. Postma

   Leading Article 27 November 2012 Pages: 523 - 535

   

2. Healthcare Rationing in Spain

   • Rosa Rodríguez-Monguió
   • Fernando Antoñanzas Villar

   Review Article 27 November 2012 Pages: 537 - 548

   

3. The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy

   • George W. Carides
   • Shahnaz Shahinfar
   • Barry M. Brenner

   Original Research Article 27 November 2012 Pages: 549 - 558

   

4. The Effects of Type 1 Diabetes and its Long-Term Complications on Physical and Mental Health Status

   • Jarmo Hahl
   • Helena Hämäläinen
   • Olli Simell

   Original Research Article 27 November 2012 Pages: 559 - 569

   

5. Cost Effectiveness of Enoxaparin as Prophylaxis against Venous Thromboembolic Complications in Acutely Ill Medical Inpatients

   • Peter K. Schädlich
   • Michael Kentsch
   • Eduard Huppertz

   Original Research Article 27 November 2012 Pages: 571 - 591

   

6. Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients

   • George Dranitsaris
   • Mark Vincent
   • Mark Crowther

   Original Research Article 27 November 2012 Pages: 593 - 607

   

7. Is the Childhood Asthma Questionnaire a Good Measure of Health-Related Quality of Life of Asthmatic Children in Asia?

   • Lee-Yee Chong
   • Oh-Moh Chay
   • Li Shu-Chuen

   Original Research Article 27 November 2012 Pages: 609 - 621

   

8. Modelling the Cost Effectiveness of Cholinesterase Inhibitors in the Management of Mild to Moderately Severe Alzheimer’s Disease

   • Nick Bosanquet
   • Andrew Yeates

   Correspondence 27 November 2012 Pages: 623 - 625

9. The Authors’ Reply

   • Colin Green
   • Joanna Picot
   • Andrew Clegg

   Correspondence 27 November 2012 Pages: 625 - 626